Rich Casey is President and Chief Executive Officer of Neuraltus Pharmaceuticals. Rich’s 40-year career in the pharmaceutical and biotechnology industries includes 11 years as Chairman and CEO of Scios (1987 – 1998). During his tenure at Scios, the Company successfully developed NATRECOR® (nesiritide) for acute congestive heart failure, which subsequently was approved in 2002. Scios was sold to Johnson & Johnson for $2.4 billion the following year.

Prior to joining Scios, Rich was Executive Vice President, Pharmaceuticals, at ALZA Corporation, responsible for all manufacturing, marketing and business development activities at the company. Previously, he held senior management roles at Syntex Corporation, including Vice President of Sales, Syntex Laboratories, and General Manager, Syntex Medical Diagnostics. Rich began his career at Eli Lilly in the sales, marketing and market research areas. He has served on the Board of Directors of numerous companies, including Scios, Karo Bio AB, Guilford Pharmaceuticals, Vivus Inc., Synsorb Biotech Inc., Nexell Therapeutics, and Rockeby biomed, Ltd. Mr. Casey received both his BS degree in Chemistry and his MBA degree from Stanford University.